{"schema_version":"secwatch.filing_event.v1","accession":"0001501697-26-000072","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2026-09-08T11:15:54+00:00","discovered_at":"2026-09-08T11:20:00.552740+00:00","generated_at":"2026-09-08T11:20:10.781205+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA agrees to X4's reduced 4WARD trial sample size (176 to 126); topline data expected H1 2028","bullets":["FDA agreed to cut 4WARD Phase 3 sample size from 176 to 126 patients, preserving power for co-primary endpoints.","Safety database deemed acceptable to support potential sNDA for mavorixafor in chronic neutropenia.","Enrollment of 4WARD expected to complete by end of 2026; topline data in H1 2028.","Mavorixafor targets ~15,000 patients with serious/recurring infections due to chronic neutropenia."],"urls":{"canonical":"https://secwatch.observer/filing/0001501697-26-000072","json":"https://secwatch.observer/filing/0001501697-26-000072.json","markdown":"https://secwatch.observer/filing/0001501697-26-000072.md","text":"https://secwatch.observer/filing/0001501697-26-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000072/0001501697-26-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000072/xfor-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T11:20:10.781205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}